5608 Results

People

  1. Motzer
    Motzer
  2. Scher
    Scher
  3. Solit
    Solit
  4. Morris
    Morris
  5. Bajorin
    Bajorin
  6. Rosenberg
    Rosenberg
  7. Berger
    Berger
  8. Iyer
    Iyer
  9. Reuter
    Reuter
  10. Feldman
    Feldman

Groups

  1. Genitourinary Oncology Service (5608)
  2. Solid Tumor Oncology Division (5608)
  3. Department of Medicine (5598)
  4. GSK Faculty (1640)
  5. Human Oncology and Pathogenesis Program (1139)
  6. Department of Pathology and Laboratory Medicine (1034)
  7. Surgery (1000)
  8. Epidemiology and Biostatistics (864)
  9. Survivorship Research (773)
  10. Urology (769)
  1. "Genitourinary Oncology Service"
Formats
  1. Journal Article (2745)
  2. Meeting Abstract (2507)
  3. Review (113)
  4. Book Section (82)
  5. Editorial (52)
  6. Correspondence (33)
  7. Conference Paper (29)
  8. Guidelines (24)
  9. Research Letter (15)
  10. Book Whole (4)
  11. Miscellaneous (4)
Groups
  1. Genitourinary Oncology Service (5608)
  2. Solid Tumor Oncology Division (5608)
  3. Department of Medicine (5598)
  4. GSK Faculty (1640)
  5. Human Oncology and Pathogenesis Program (1139)
  6. Department of Pathology and Laboratory Medicine (1034)

More Groups

People
  1. Robert Motzer (1243)
  2. Howard Scher (1130)
  3. David Solit (779)
  4. Dean Bajorin (657)
  5. Michael Morris (577)
  6. Jonathan Rosenberg (510)

More People

Years
  1. 2025 (118)
  2. 2024 (293)
  3. 2023 (283)
  4. 2022 (314)
  5. 2021 (341)
  6. 2020 (352)

More Years

Publications
  1. Journal of Clinical Oncology (1697)
  2. Annals of Oncology (303)
  3. Clinical Cancer Research (282)
  4. Cancer Research (245)
  5. Cancer (125)
  6. European Urology (118)

More Publications

Publishers
  1. American Society of Clinical Oncology (1757)
  2. American Association for Cancer Research (688)
  3. Oxford University Press (408)
  4. Elsevier Science, Inc. (389)
  5. Elsevier Inc. (384)
  6. Nature Publishing Group (294)

More Publishers

Results (5608)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Towards a unified model of RAF inhibitor resistance
    Journal Article

    Solit, D. B.; Rosen, N.
    Cancer Discovery (2014)

    Fulltext@MSK | Save
  • Sunitinib objective response in metastatic renal cell carcinoma: Analysis of 1059 patients treated on clinical trials
    Journal Article

    Molina, A. M.; Lin, X.; Korytowsky, B.; Matczak, E.; Lechuga, M. J.; Wiltshire, R.; Motzer, R. J.
    European Journal of Cancer (2014)

    Fulltext@MSK | Save
  • The evolving understanding of microRNA in bladder cancer
    Journal Article

    Guancial, E. A.; Bellmunt, J.; Yeh, S.; Rosenberg, J. E.; Berman, D. M.
    Urologic Oncology: Seminars and Original Investigations (2014)

    Fulltext@MSK | Save
  • Long-term mortality in patients with germ cell tumors: Effect of primary cancer site on cause of death
    Journal Article

    Alanee, S. R.; Feldman, D. R.; Russo, P.; Konety, B.
    Urologic Oncology: Seminars and Original Investigations (2014)

    Fulltext@MSK | Save
  • General chemotherapy imaging
    Book Section

    Torrisi, J. M.; Iyriboz, T. A.; Xiao, H.
    In Bach, A. M.; Zhang, J. (Eds.) Atlas of Genitourinary Oncological Imaging (2013)

    Fulltext@MSK | Save
  • Phase II trial of (177)lutetium radiolabeled anti-PSMA antibody J591 ((177)Lu-J591) for metastatic castrate-resistant prostate cancer (metCRPC): Survival update and expansion cohort with biomarkers
    Meeting Abstract

    Tagawa, S. T.; Akhtar, N. H.; Osborne, J.; Christos, P. J.; Vallabhajosula, S.; Goldsmith, S. J.; Kahn, R.; Ecker, C.; Beltran, H.; Morris, M. J.; more...
    Journal of Clinical Oncology (2013)

    Fulltext@MSK | Save
  • ARN-509 in men with high-risk nonmetastatic castration-resistant prostate cancer (CRPC)
    Meeting Abstract

    Smith, M. R.; Antonarakis, E. S.; Ryan, C. J.; Berry, W. R.; Shore, N.; Liu, G.; Alumkal, J. J.; Higano, C. S.; Maneval, E. C.; Rathkopf, D. E.
    Journal of Clinical Oncology (2013)

    Fulltext@MSK | Save
  • Outcomes in elderly patients with metastatic castration-resistant prostate cancer (mCRPC) treated with the androgen receptor inhibitor enzalutamide: Results from the phase III AFFIRM trial
    Meeting Abstract

    Sternberg, C. N.; De Bono, J. S.; Chi, K. N.; Fizazi, K.; Mulders, P.; Hirmand, M.; Forer, D.; Scher, H. I.
    Journal of Clinical Oncology (2013)

    Fulltext@MSK | Save
  • Dissecting the therapeutic effects of anti-CTLA-4 and ADT in a murine hormone-sensitive prostate cancer
    Meeting Abstract

    Subudhi, S. K.; Montalvo-Ortiz, W.; Scher, H. I.; Allison, J. P.
    Journal of Clinical Oncology (2013)

    Fulltext@MSK | Save
  • Treatment outcome with mTOR inhibitors for 65 cases of non-clear cell renal cell carcinoma: Association of long-term responses and oncogenomic events
    Meeting Abstract

    Voss, M. H.; Bastos, D. A.; Karlo, C.; Patil, S.; Ajeti, A.; Hakimi, A. A.; Feldman, D. R.; Molina, A. M.; Berger, M. F.; Hsieh, J.; more...
    Journal of Clinical Oncology (2013)

    Fulltext@MSK | Save